Two-way messaging therapy for depression and anxiety: longitudinal response trajectories.
Anxiety
Depression
Digital health
Longitudinal design
Messaging therapy
Telemedicine
Text therapy
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
12 06 2020
12 06 2020
Historique:
received:
07
10
2019
accepted:
09
06
2020
entrez:
14
6
2020
pubmed:
14
6
2020
medline:
4
11
2020
Statut:
epublish
Résumé
Telemedicine is a strategy for overcoming barriers to access evidence-based psychotherapy. Digital modalities that operate outside session-based treatment formats, such as ongoing two-way messaging, may further address these challenges. However, no study to date has established suitability criteria for this medium. A large outpatient sample (n = 10,718) engaged in daily messaging with licensed clinicians from a telemedicine provider. Patients consisted of individuals from urban and rural settings in all 50 states of the US, who signed up to the telemedicine provider. Using a longitudinal design, symptoms changes were observed during a 12 week treatment course. Symptoms were assessed from baseline every three weeks using the Patient Health Questionnaire (PHQ-9) for depression, and the Generalized Anxiety Disorder (GAD-7) for anxiety. Demographics and engagement metrics, such as word count for both patients and therapists, were also assessed. Growth mixture modeling was used to tease apart symptoms trajectories, and identify predictors of treatment response. Two subpopulations had GAD-7 and PHQ-9 remission outcomes (Recovery and Acute Recovery, 30.7% of patients), while two others showed amelioration of symptoms (Depression and Anxiety Improvement, 36.9% of patients). Two subpopulations experienced no changes in symptoms (Chronic and Elevated Chronic, 32.4% of patients). Higher use of written communication, patient characteristics, and engagement metrics reliably distinguished patients with the greatest level of remission (Recovery and Acute Recovery groups). Remission of depression and anxiety symptoms was observed during delivery of psychotherapy through messaging. Improvement rates were consistent with face-to-face therapy, suggesting the suitability of two-way messaging psychotherapy delivery. Characteristics of improving patients were identified and could be used for treatment recommendation. These findings suggest the opportunity for further research, to directly compare messaging delivery with a control group of treatment as usual. Clinicaltrials.gov Identifier: NCT03699488, Retrospectively Registered October 8, 2018.
Sections du résumé
BACKGROUND
Telemedicine is a strategy for overcoming barriers to access evidence-based psychotherapy. Digital modalities that operate outside session-based treatment formats, such as ongoing two-way messaging, may further address these challenges. However, no study to date has established suitability criteria for this medium.
METHODS
A large outpatient sample (n = 10,718) engaged in daily messaging with licensed clinicians from a telemedicine provider. Patients consisted of individuals from urban and rural settings in all 50 states of the US, who signed up to the telemedicine provider. Using a longitudinal design, symptoms changes were observed during a 12 week treatment course. Symptoms were assessed from baseline every three weeks using the Patient Health Questionnaire (PHQ-9) for depression, and the Generalized Anxiety Disorder (GAD-7) for anxiety. Demographics and engagement metrics, such as word count for both patients and therapists, were also assessed. Growth mixture modeling was used to tease apart symptoms trajectories, and identify predictors of treatment response.
RESULTS
Two subpopulations had GAD-7 and PHQ-9 remission outcomes (Recovery and Acute Recovery, 30.7% of patients), while two others showed amelioration of symptoms (Depression and Anxiety Improvement, 36.9% of patients). Two subpopulations experienced no changes in symptoms (Chronic and Elevated Chronic, 32.4% of patients). Higher use of written communication, patient characteristics, and engagement metrics reliably distinguished patients with the greatest level of remission (Recovery and Acute Recovery groups).
CONCLUSIONS
Remission of depression and anxiety symptoms was observed during delivery of psychotherapy through messaging. Improvement rates were consistent with face-to-face therapy, suggesting the suitability of two-way messaging psychotherapy delivery. Characteristics of improving patients were identified and could be used for treatment recommendation. These findings suggest the opportunity for further research, to directly compare messaging delivery with a control group of treatment as usual.
TRIAL REGISTRATION
Clinicaltrials.gov Identifier: NCT03699488, Retrospectively Registered October 8, 2018.
Identifiants
pubmed: 32532225
doi: 10.1186/s12888-020-02721-x
pii: 10.1186/s12888-020-02721-x
pmc: PMC7291694
doi:
Banques de données
ClinicalTrials.gov
['NCT03699488']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
Biol Psychiatry. 2002 Sep 15;52(6):610-30
pubmed: 12361671
Ann Behav Med. 2006 Dec;32(3):254-8
pubmed: 17107299
Stat Anal Data Min. 2017 Dec;10(6):363-377
pubmed: 29403567
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Worldviews Evid Based Nurs. 2012 Apr;9(2):66-77
pubmed: 22268959
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
pubmed: 10767867
JAMA Psychiatry. 2019 Jul 1;76(7):700-707
pubmed: 30994877
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA. 2001 Dec 19;286(23):2947-55
pubmed: 11743835
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
BMC Psychiatry. 2008 Jul 22;8:60
pubmed: 18647396
Aust N Z J Psychiatry. 2017 Dec;51(12):1227-1239
pubmed: 27733709
Am J Prev Med. 2009 Feb;36(2):165-73
pubmed: 19135907
Am J Psychiatry. 2004 Sep;161(9):1626-34
pubmed: 15337653
J Med Internet Res. 2016 Jun 10;18(6):e135
pubmed: 27287668
JAMA Psychiatry. 2015 Oct;72(10):1021-8
pubmed: 26288246
J Consult Clin Psychol. 2009 Apr;77(2):203-11
pubmed: 19309180
BMJ. 2018 Dec 13;363:k5094
pubmed: 30545967
Telemed J E Health. 2017 Mar;23(3):240-247
pubmed: 27797646
Telemed J E Health. 2003 Spring;9(1):49-55
pubmed: 12699607
Am Psychol. 1995 Dec;50(12):965-74
pubmed: 8561380
Arch Gen Psychiatry. 2001 Jan;58(1):55-61
pubmed: 11146758
Curr Psychiatry Rep. 2018 Aug 28;20(10):85
pubmed: 30155593
Am Psychol. 2014 Jan;69(1):1-18
pubmed: 23915401
Lancet. 2009 Aug 22;374(9690):628-34
pubmed: 19700005
Adm Policy Ment Health. 2011 Nov;38(6):495-503
pubmed: 21298475
J Gen Intern Med. 1997 Jul;12(7):403-6
pubmed: 9229277
Cyberpsychol Behav. 2005 Apr;8(2):172-7
pubmed: 15938657
J Gen Intern Med. 2002 Feb;17(2):103-11
pubmed: 11841525
Arch Gen Psychiatry. 1989 Nov;46(11):971-82; discussion 983
pubmed: 2684085
Fam Pract. 2006 Jun;23(3):325-48
pubmed: 16476700
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617